

Oklahoma Health Care Authority

Drug Utilization Review Board (DUR Board)

Meeting – July 9, 2025 @ 4:00pm

at the

Oklahoma Health Care Authority (OHCA)

4345 N. Lincoln Blvd.

Oklahoma City, Oklahoma 73105

NOTE: ***The DUR Board will meet at 4:00pm at OHCA (see address above). There will be Zoom access to this meeting; however, Zoom access will be set up in view-only mode with no voting, speaking, video, or chat box privileges. Zoom access will allow for viewing of the presentation slides as well as audio of the presentations and discussion during the meeting; however, the DUR Board meeting will not be delayed or rescheduled due to any technical issues that may arise.***

AGENDA

Discussion and action on the following items:

Items to be presented by Dr. Haymore, Chairman:

1. Call to Order

A. Roll Call – Dr. Wilcox

DUR Board Members:

Dr. Cassidy Blaiss –	participating in person
Mr. Kenneth Foster –	participating in person
Dr. Bret Haymore –	participating in person
Dr. Bethany Holderread –	participating in person
Dr. Craig Kupiec –	participating in person
Dr. Lee Muñoz –	participating in person
Dr. James Osborne –	participating in person
Dr. Edna Patatanian –	participating in person
Dr. Jennifer Weakley –	participating in person

Viewing Access Only via Zoom:

Please register for the meeting at:

https://oklahoma.zoom.us/webinar/register/WN_B7-m8jKcQWaA9HEiV7QRQA

After registering, you will receive a confirmation email containing information about joining the webinar.

Or join by phone:

Dial: +1-602-753-0140 or +1-669-219-2599

Webinar ID: 928 6649 0447

Passcode: 80744869

Public Comment for Meeting:

- Speakers who wish to sign up for public comment at the OHCA DUR Board meeting may do so in writing by visiting the DUR Board page on the OHCA website at www.oklahoma.gov/ohca/about/boards-and-committees/drug-utilization-review/dur-board and completing the [Speaker Registration Form](#). Completed Speaker Registration forms should be submitted to DURPublicComment@okhca.org. Forms must be received after the DUR Board agenda has been posted and no later than 24 hours before the meeting.
- The DUR Board meeting will allow public comment and time will be limited to 40 minutes total for all speakers during the meeting. Each speaker will be given 5 minutes to speak at the public hearing. If more than 8 speakers properly request to speak, time will be divided evenly.
- Only 1 speaker per manufacturer will be allowed.
- Any speakers who sign up for public comment must attend the DUR Board meeting in person at OHCA (see above address). Public comment through Zoom will not be allowed for the DUR Board meeting.

Items to be presented by Dr. Haymore, Chairman:

2. Public Comment Forum

- A. Acknowledgement of Speakers for Public Comment

Items to be presented by Dr. Haymore, Chairman:

3. Action Item – Approval of DUR Board Meeting Minutes – See Appendix A

- A. June 11, 2025 DUR Board Meeting Minutes
- B. June 11, 2025 DUR Board Recommendations Memorandum
- C. Correspondence

Non-presentation items reviewed by Dr. DeRemer, Dr. Haymore, Chairman:

4. Update on Medication Coverage Authorization Unit – See Appendix B

- A. Pharmacy Help Desk Activity for June 2025
- B. Medication Coverage Activity for June 2025

Items to be presented by Dr. Travers, Dr. Haymore, Chairman:

5. Chronic Medication Adherence (CMA) Program Update – See Appendix C

- A. Introduction
- B. Conclusions

Items to be presented by Dr. O'Halloran, Dr. Haymore, Chairman:

6. Action Item – Vote to Prior Authorize Cobenfy™ (Xanomeline/Trospium), Erzofri® [Paliperidone Palmitate Extended-Release (ER) Injection], and Opienza™ (Aripiprazole Oral Film) and Update the Approval Criteria for the Atypical Antipsychotic Medications – See Appendix D

- A. Market News and Updates

- B. Cobenfy™ (Xanomeline/Trospium) Product Summary
- C. Cost Comparisons
- D. College of Pharmacy Recommendations

Items to be presented by Dr. Moss, Dr. Haymore, Chairman:

7. Action Item – Vote to Prior Authorize Carbamazepine 200mg Chewable Tablet, Femlyv™ [Norethindrone Acetate/Ethinyl Estradiol Orally Disintegrating Tablet (ODT)], Focinvez™ (Fosaprepitant Injection), Imkeldi (Imatinib Oral Solution), IVRA (Melfalan 90mg/mL Injection), Myhibbin™ (Mycophenolate Mofetil Oral Suspension), Ondansetron 16mg ODT, Tezruly™ (Terazosin Oral Solution), Topiramate 50mg Sprinkle Capsule, Veltassa® (Patiromer) 1g Powder Packet, and Vigafyde™ (Vigabatrin Oral Solution) and Update the Approval Criteria for the Various Special Formulations – See Appendix E

- A. Introduction
- B. Product Summaries and College of Pharmacy Recommendations
- C. College of Pharmacy Additional Recommendations

Items to be presented by Dr. Sinko, Dr. Haymore, Chairman:

8. Action Item – Vote to Prior Authorize Avmapki™ Fakzynja™ Co-Pack (Avutometinib and Defactinib) and Update the Approval Criteria for the Genitourinary and Gynecologic Cancer Medications – See Appendix F

- A. Market News and Updates
- B. Avmapki™ Fakzynja™ Co-Pack (Avutometinib and Defactinib) Product Summary
- C. College of Pharmacy Recommendations

Non-presentation items reviewed by Dr. Sinko, Dr. Haymore, Chairman:

9. Annual Review of Colorectal Cancer (CRC) Medications – See Appendix G

- A. Current Prior Authorization Criteria
- B. Utilization of CRC Medications
- C. Prior Authorization of CRC Medications
- D. Market News and Updates
- E. College of Pharmacy Recommendations
- F. Utilization Details of CRC Medications

Items to be presented by Dr. DeRemer, Dr. Haymore, Chairman:

10. Action Item – Annual Review of Defencath® (Taurolidine/Heparin) – See Appendix H

- A. Current Prior Authorization Criteria
- B. Utilization of Defencath® (Taurolidine/Heparin)
- C. Prior Authorization of Defencath® (Taurolidine/Heparin)
- D. Market News and Updates
- E. College of Pharmacy Recommendations
- F. Utilization Details of Defencath® (Taurolidine/Heparin)

Items to be presented by Dr. DeRemer, Dr. Haymore, Chairman:

11. Action Item – Annual Review of Constipation and Diarrhea Medications – See Appendix I

- A. Current Prior Authorization Criteria
- B. Utilization of Constipation and Diarrhea Medications
- C. Prior Authorization of Constipation and Diarrhea Medications
- D. Market News and Updates
- E. College of Pharmacy Recommendations
- F. Utilization Details of Constipation and Diarrhea Medications

Items to be presented by Dr. Wilson, Dr. Haymore, Chairman:

12. Annual Review of Testosterone Products and 30-Day Notice to Prior Authorize Azmiro™ (Testosterone Cypionate 200mg/mL Syringe) and Undecatrex™ (Testosterone Undecanoate Capsule) – See Appendix J

- A. Current Prior Authorization Criteria
- B. Utilization of Testosterone Products
- C. Prior Authorization of Testosterone Products
- D. Market News and Updates
- E. Cost Comparison
- F. College of Pharmacy Recommendations
- G. Utilization Details of Testosterone Products

Items to be presented by Dr. Moss, Dr. Haymore, Chairman:

13. Annual Review of Epidermolysis Bullosa (EB) Medications and 30-Day Notice to Prior Authorize Zevaskyn™ (Prademagene Zamikeracel) – See Appendix K

- A. Current Prior Authorization Criteria
- B. Utilization of EB Medications
- C. Prior Authorization of EB Medications
- D. Market News and Updates
- E. Zevaskyn™ (Prademagene Zamikeracel) Product Summary
- F. College of Pharmacy Recommendations
- G. Utilization Details of EB Medications

Items to be presented by Dr. O'Halloran, Dr. Haymore, Chairman:

14. Annual Review of Alzheimer's Disease Medications and 30-Day Notice to Prior Authorize Zunveyl® (Benzgalantamine) – See Appendix L

- A. Current Prior Authorization Criteria
- B. Utilization of Alzheimer's Disease Medications
- C. Prior Authorization of Alzheimer's Disease Medications
- D. Market News and Updates
- E. Zunveyl® (Benzgalantamine) Product Summary
- F. College of Pharmacy Recommendations
- G. Utilization Details of Alzheimer's Disease Medications

Non-presentation items reviewed by Dr. DeRemer, Dr. Haymore, Chairman:

15. U.S. Food and Drug Administration (FDA) and Drug Enforcement Administration (DEA) Updates – See Appendix M

Non-presentation items reviewed by Dr. Adams, Dr. Haymore, Chairman:

16. Future Business* (Upcoming Product and Class Reviews)

No live DUR Board Meeting is scheduled for August 2025. August 2025 will be a packet-only meeting.

- A. Iron Products
- B. Opioid Analgesics and Medication-Assisted Treatment (MAT) Medications
- C. Topical Corticosteroids
- D. Various Systemic Antibiotics

*Future product and class reviews subject to change.

17. Adjournment

NOTE: An analysis of the atypical [Aged, Blind, and Disabled (ABD)] patient subgroup of the Oklahoma Medicaid population has been performed pertaining to all recommendations included in this DUR Board meeting packet to ensure fair and knowledgeable deliberation of the potential impact of the recommendations on this patient population.

NOTE: Oklahoma Medicaid transitioned from a fee-for-service (FFS) pharmacy benefit to a managed care pharmacy benefit for most members on April 1, 2024. At that time, the majority of SoonerCare members were transitioned to one of the three managed care SoonerSelect plans: Aetna, Humana, or Oklahoma Complete Health. SoonerSelect data has been provided to the College of Pharmacy and has been used in analyses throughout this DUR Board meeting packet. The data included in this DUR Board meeting packet combines FFS and managed care utilization data. The managed care utilization and prior authorization (PA) data reported in this packet is based solely on the data provided by the SoonerSelect plans.